FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI) software EchoGo® Amyloidosis, which may help bolster early detection of cardiac amyloidosis, a diagnosis that is commonly missed in high-risk patients with heart failure and preserved ejection fraction (HFpEF).
Requiring only a single apical four-chamber echocardiography video clip, the EchoGo Amyloidosis software facilitates improved accuracy in the detection of cardiac amyloidosis, according to Ultromics, the manufacturer of the software.
The newly FDA-cleared EchoGo Amyloidosis AI software has demonstrated 84.5 percent sensitivity for diagnosing cardiac amyloidosis in patients with heart failure that are 65 years of age and older, according to Ultromics, the developer of the software. (Image courtesy of Ultromics.)
Citing research submitted to the FDA, Ultromics noted that EchoGo Amyloidosis has 84.5 percent sensitivity and 89.7 percent specificity in diagnosing cardiac amyloidosis in patients with heart failure that are 65 years of age and older.
The company also pointed out that the AI software’s has demonstrated consistent sensitivity rates across different subtypes of amyloidosis such as AL (primary) amyloidosis (84.4 percent), hereditary transthyretin amyloidosis (TTRv) (86.3 percent), and wild-type transthyretin amyloidosis (85.8 percent).
“Improving the detection of cardiac amyloidosis is vital as early detection provides the greatest therapeutic benefit for patients. Novel AI-based diagnostic tools such as EchoGo® Amyloidosis from Ultromics should help facilitate disease identification, particularly in clinics and hospitals restricted by expertise and resource,” noted Sanjiv J. Shah, M.D., the director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program and the Center for Deep Phenotyping and Precision Medicine in the Institute for Augmented Intelligence in Medicine at the Northwestern University Feinberg School of Medicine.
Recent Videos
Related Content
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Article
Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
